MedTrace Logo

The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma

NCT05576571 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-10-17

No results posted yet for this study

Summary

Patients with liver cancer expected to undergo radiofrequency ablation or transvascular embolization. Relevant tumor markers (AFP and methylation analysis) were performed. The two data are then counted and compared.

Conditions

  • Serum Tumor Markers

Interventions

DIAGNOSTIC_TEST

Met-score

methylation analysis

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Kai-Wen Huang, MD, PhD · study principal investigator

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-16
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05576571 on ClinicalTrials.gov